Sanofi has announced the publication of positive results from a Phase III clinical trial of Dupixent (dupilumab) in one to 11-year-old children with eosinophilic esophagitis (EoE).
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,